Biocon Biologics has reached a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the ...

Paving the way for launch of Yesafili? in the United States Biocon Biologics (BBL), subsidiary of Biocon, announced today a settlement and license agreement with Regeneron that clears the way to ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: ...